Experimentation with strategy and the evolution of dynamic capability in the Indian pharmaceutical sector

Industrial and Corporate Change

Volumn 18, Issue 4, 2009, Pages 729-759

  Athreye, Suma ^a   Kale, Dinar ^b   Ramani, Shyama V ^c,d  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

^c CEMAGREF   (France)

^d ECOLE POLYTECHNIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EXPERIMENTAL STUDY; INDUSTRIAL POLICY; INTELLECTUAL PROPERTY RIGHTS; PHARMACEUTICAL INDUSTRY; POLICY IMPLEMENTATION; REGULATORY FRAMEWORK; STRATEGIC APPROACH; TECHNOLOGY POLICY;

ASIA; EURASIA; INDIA; SOUTH ASIA;

EID: 67949086862     PISSN: 09606491     EISSN: 14643650     Source Type: Journal    
DOI: 10.1093/icc/dtp024     Document Type: Article

References (18)

1. Chaudhuri, S. (2007), 'Is product patent protection necessary in developing countries for innovation? R&D by Indian pharmaceutical companies after TRIPS,' Indian Institute of Management: Calcutta.
2. Eisenhardt, K. M. and J. Martin (2000), 'Dynamic capabilities: What are they?,' Strategic Management Journal, 21, 1105-1121.
3. Gehl Sampath, P. (2006), 'Indian pharma within global reach?,' UNU-Merit Working Paper, 2006-031. United Nations University: Maastrict.
4. Greene, W. (2007), 'The emergence of India's pharmaceutical industry and implications for the U.S. generic drug market,' Office of Economics Working Paper. U.S. International Trade Commission: Washington, DC.
5. Kale, D. J. (2005), 'Re-developing a knowledge creation capability: innovating in Indian pharmaceutical industry under TRIPS regime,' Unpublished PhD Thesis. The Open University: UK.
6. Kale, D. J and S. E. Little (2007), 'From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry,' Technology Analysis and Strategic Management, 19, 589-611.
7. Nelson, R. and S. Winter (1982), An Evolutionary Theory of Economic Change. Harvard University Press: Cambridge, MA.
8. OPPI (2001), 'OPPI Pharmaceutical Compendium,' Mumbai: Organisation of Pharmaceutical Producers of India, Volumes 2001, 2004.
9. Penrose, E. T. (1959), The Theory of the Growth of the Firm. Wiley: New York.
10. Pradhan, J. (2007), 'New policy regime and small pharmaceutical firms in India,' Working Paper 2007/02. Institute for Studies in Industrial Development: New Delhi.
11. Ramani, S. V. (2002), 'Who's interested in biotechnology: R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms,' Research Policy, 31, 381-398.
12. Ramani, S. V. and A. Maria (2005), 'TRIPS and its possible impact on the biotech based segment of the Indian pharmaceutical industry,' Economic and Political Weekly, Feb 12-18, 675-683.
13. Ramani, S. V. and C. Putz (2001), 'Resources, performance and strategy: a statistical examination of the integration of biotechnology in the Indian pharmaceutical sector,' International Journal of Biotechnology 3, 374-390.
14. Rumelt, R. P. (1984), 'Towards a strategic theory of the firm,' in R. B. Lamb (ed.), Competitive Strategic Management. Prentice-Hall: Englewood Cliffs, NJ.
15. Teece, D. J., G. Pisano and A. Shuen (1997), 'Dynamic capabilities and strategic management,' Strategic Management Journal, 18, 509-533.
16. Teece, D. J. (1998), 'Capturing value from knowledge assets: The new economy, markets for know-how, and intangible assets,' California Management Review, 40, 55-79.
17. Utterback, J. (1996), Mastering the Dynamics of Innovation. Harvard Business School Press: Cambridge, MA.
18. Winter, S. (2003), 'Understanding dynamic capabilities,' Strategic Management Journal, 24, 991-995.